Neuren Pharmaceutica (NURPF) 0.0750 $NURPF Glob
Post# of 273249
Posted On: 10/11/2015 6:49:58 AM
Neuren Pharmaceutica (NURPF) 0.0750 $NURPF
Global Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Sep 08, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/32f36p/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arcturus Therapeutics, Inc - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - Polyneuron Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - Teijin Pharma Limited Drug Profiles - (immune globulin (human) hyaluronidase (recombinant)) - Cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - immune globulin (human) - LUNAR-102 - Monoclonal Antibody for CIDP - NNZ-2591 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - PN-1007 - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/32f36p/peripheral
INSY: 25.65 (+0.64), PFE: 33.24 (+0.15)
Fragile X Syndrome Pipeline Review 2015 - 10 Companies & 20 Company Profiles
M2 - Fri Jul 10, 3:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js4sb7/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aelis Farma S.A.S. - Alcobra Ltd - Confluence Pharmaceuticals LLC - Cortex Pharmaceuticals, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Marinus Pharmaceuticals, Inc. - MI.TO. Technology S.r.L. - Neuren Pharmaceuticals Limited - Selvita SA Drug Profiles - acamprosate calcium - basimglurant - Bryostatin-1 - cercosporamide - CX-929 - Drugs to Inhibit mGluR5 for Fragile X Syndrome - flindokalner - gaboxadol - ganaxolone - Metadoxine ER - minocycline - NNZ-2591 - SEL-203 - Small Molecule for FXTAS - Small Molecule to Activate Epsilon PKC for Fragile X Syndrome - Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Small Molecules to Agonize 5-HT7 for Fragile X Syndrome - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - SRT-278 - trofinetide For more information visit http://www.researchandmarkets.com/research/js4sb7/fragile_x
MRNS: 10.01 (+0.47), ADHD: 5.66 (+0.17), LLY: 86.14 (+2.37)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 0.22 (+0.01), CNCE: 20.87 (+0.62), ATHX: 1.14 (-0.01), KPTI: 11.75 (+0.04), CUR: 1.33 (+0.03)
Traumatic Brain Injury: Therapeutic and Diagnostic Pipeline Assessment and Commercial Prospects
M2 - Thu Apr 02, 4:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37s9xj/traumatic_brain) has announced the addition of the "Traumatic Brain Injury: Therapeutic and Diagnostic Pipeline Assessment and Commercial Prospects" report to their offering. Traumatic brain injury (TBI) is the single leading cause of death and disability worldwide in children and young adults following an injury. With around 10 million new cases diagnosed and 1.5 million deaths occurring per annum globally; this silent' epidemic accounts for more fatalities than diabetes or lung cancer. Despite three decades of intensive research and development effort, translating benchside to bedside success remains the single greatest challenge in TBI. All 33 Phase III TBI clinical trials testing the efficacy of neuroprotective agents have failed over the past 20 years. Consequently, no FDA-approved TBI therapy exists. Nevertheless, 2013 witnessed the creation of a National Research Action Plan (NRAP) to address the current unmet needs in TBI. Point-of-care (POC) diagnostic devices look set to revolutionize the diagnosis of TBI. By year end 2014, a number of POC diagnostic devices may be approved by the FDA. Key Features: - Identification of the major challenges within TBI R&D including unmet needs, clinical trial design and alternative R&D approaches, the potential of biomarkers, regulatory hurdles and ethical issues - Clinical and commercial analysis of key Phase III TBI drug candidates and point-of-care diagnostic devices - An assessment of the potential financial TBI market, with seven major market forecasts to 2020 for key pipeline drug candidates and point-of-care diagnostic devices Key Topics Covered: 1. EXECUTIVE SUMMARY 2. TRAUMATIC BRAIN INJURY: DISEASE BACKGROUND 3. THE EPIDEMIOLOGY AND FINANCIAL IMPLICATIONS OF TBI 4. THE CURRENT MANAGEMENT OF TBI 5. THE MAJOR CHALLENGES OF TBI RESEARCH AND DEVELOPMENT (R&D) 6. UNMET NEEDS IN THE TBI MARKET 7. TBI THERAPEUTIC PIPELINE ANALYSIS 8. OVERVIEW OF KEY ACADEMIC AND GOVERNMENTAL TBI RESEARCH 9. POTENTIAL TBI BIOMARKERS 10. TBI POINT OF CARE DIAGNOSTIC DEVICES PIPELINE ANALYSIS 11. FINANCIAL FORECAST OF THE POTENTIAL TBI MARKET 12. COMPANY BRIEFS - Banayan Biomarkers Inc. - BHR Pharma LLC - Biodirection Inc. - Brainscope Company Inc. - Cerora Inc. - ElMindA Ltd. - Grace Laboratories LLC - KeyNeurotek Pharmaceuticals AG - Luoxis Diagnostics - Neuro Assessment Systems - Neurohealing Pharmaceuticals - Neuren Pharmaceuticals Ltd. - Neurovive Pharmaceuticals AB - Oxygen Biotherapeutics Inc. - Phlogistix LLC - Remedy Pharmaceuticals Inc. - SFC Fluidics LLC - TEVA Pharmaceutical Industries Ltd. - Vasopharm For more information visit http://www.researchandmarkets.com/research/37...atic_brain
TEVA: 58.96 (-0.28)
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Pipeline Review 2015 - 10 Drug Profiles & 16 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mh4n22/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - RegeneRx Biopharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - Monoclonal Antibody for CIDP - NNZ-2591 - NP-1998 - NRP-2945 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides for Neuropathic Pain and Peripheral Neuropathy - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/mh4n22/peripheral
INSY: 25.65 (+0.64), PFE: 33.24 (+0.15), ACOR: 29.89 (-0.22)
Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 7:31AM CST
The report "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-n...eport.html .
PFE: 33.24 (+0.15)
Fragile X Syndrome Therapeutic Pipeline Market by Companies & Drugs Profile Review H2 2014
PRWeb - Sun Dec 07, 1:31PM CST
The report "Fragile X Syndrome Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. Fragile X Syndrome is the most common inherited form of mental problems and this disease caused by changes in a single X. Complete Report is Available @ http://www.rnrmarketresearch.com/fragile-x-sy...eport.html .
MRNS: 10.01 (+0.47), PRTK: 21.00 (+0.25)
Neuren's NNZ-2566 Successful in Demonstrating Clinical Benefit in Rett Syndrome Phase 2 Trial
Marketwired - Wed Nov 12, 12:26PM CST
Highlights:
NEU: 386.98 (+2.97)
Neuren Announces Results of the NNZ-2566 Clinical Trial for Rett Syndrome
PRWeb - Tue Nov 11, 7:11PM CST
Neuren Pharmaceuticals' human clinical trial using NNZ-2566 as a potential treatment for Rett syndrome (a trial supported by Rettsyndrome.org) was completed in September of this year. On November 11, Neuren announced the results of this phase 2 placebo-controlled study, which investigated the dosing of NNZ-2566 for safety and tolerability with efficacy being studied as well. The study was carried out at Baylor College of Medicine (Drs. Daniel Glaze and Jeffery Neul), University of Alabama Birmingham (Dr. Alan Percy) and Gillette Children's Specialty Healthcare (Drs. Tim Feyma and Art Beisang).
Global Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Sep 08, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/32f36p/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arcturus Therapeutics, Inc - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - Polyneuron Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - Teijin Pharma Limited Drug Profiles - (immune globulin (human) hyaluronidase (recombinant)) - Cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - immune globulin (human) - LUNAR-102 - Monoclonal Antibody for CIDP - NNZ-2591 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - PN-1007 - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/32f36p/peripheral
INSY: 25.65 (+0.64), PFE: 33.24 (+0.15)
Fragile X Syndrome Pipeline Review 2015 - 10 Companies & 20 Company Profiles
M2 - Fri Jul 10, 3:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js4sb7/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aelis Farma S.A.S. - Alcobra Ltd - Confluence Pharmaceuticals LLC - Cortex Pharmaceuticals, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Marinus Pharmaceuticals, Inc. - MI.TO. Technology S.r.L. - Neuren Pharmaceuticals Limited - Selvita SA Drug Profiles - acamprosate calcium - basimglurant - Bryostatin-1 - cercosporamide - CX-929 - Drugs to Inhibit mGluR5 for Fragile X Syndrome - flindokalner - gaboxadol - ganaxolone - Metadoxine ER - minocycline - NNZ-2591 - SEL-203 - Small Molecule for FXTAS - Small Molecule to Activate Epsilon PKC for Fragile X Syndrome - Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Small Molecules to Agonize 5-HT7 for Fragile X Syndrome - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - SRT-278 - trofinetide For more information visit http://www.researchandmarkets.com/research/js4sb7/fragile_x
MRNS: 10.01 (+0.47), ADHD: 5.66 (+0.17), LLY: 86.14 (+2.37)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 0.22 (+0.01), CNCE: 20.87 (+0.62), ATHX: 1.14 (-0.01), KPTI: 11.75 (+0.04), CUR: 1.33 (+0.03)
Traumatic Brain Injury: Therapeutic and Diagnostic Pipeline Assessment and Commercial Prospects
M2 - Thu Apr 02, 4:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37s9xj/traumatic_brain) has announced the addition of the "Traumatic Brain Injury: Therapeutic and Diagnostic Pipeline Assessment and Commercial Prospects" report to their offering. Traumatic brain injury (TBI) is the single leading cause of death and disability worldwide in children and young adults following an injury. With around 10 million new cases diagnosed and 1.5 million deaths occurring per annum globally; this silent' epidemic accounts for more fatalities than diabetes or lung cancer. Despite three decades of intensive research and development effort, translating benchside to bedside success remains the single greatest challenge in TBI. All 33 Phase III TBI clinical trials testing the efficacy of neuroprotective agents have failed over the past 20 years. Consequently, no FDA-approved TBI therapy exists. Nevertheless, 2013 witnessed the creation of a National Research Action Plan (NRAP) to address the current unmet needs in TBI. Point-of-care (POC) diagnostic devices look set to revolutionize the diagnosis of TBI. By year end 2014, a number of POC diagnostic devices may be approved by the FDA. Key Features: - Identification of the major challenges within TBI R&D including unmet needs, clinical trial design and alternative R&D approaches, the potential of biomarkers, regulatory hurdles and ethical issues - Clinical and commercial analysis of key Phase III TBI drug candidates and point-of-care diagnostic devices - An assessment of the potential financial TBI market, with seven major market forecasts to 2020 for key pipeline drug candidates and point-of-care diagnostic devices Key Topics Covered: 1. EXECUTIVE SUMMARY 2. TRAUMATIC BRAIN INJURY: DISEASE BACKGROUND 3. THE EPIDEMIOLOGY AND FINANCIAL IMPLICATIONS OF TBI 4. THE CURRENT MANAGEMENT OF TBI 5. THE MAJOR CHALLENGES OF TBI RESEARCH AND DEVELOPMENT (R&D) 6. UNMET NEEDS IN THE TBI MARKET 7. TBI THERAPEUTIC PIPELINE ANALYSIS 8. OVERVIEW OF KEY ACADEMIC AND GOVERNMENTAL TBI RESEARCH 9. POTENTIAL TBI BIOMARKERS 10. TBI POINT OF CARE DIAGNOSTIC DEVICES PIPELINE ANALYSIS 11. FINANCIAL FORECAST OF THE POTENTIAL TBI MARKET 12. COMPANY BRIEFS - Banayan Biomarkers Inc. - BHR Pharma LLC - Biodirection Inc. - Brainscope Company Inc. - Cerora Inc. - ElMindA Ltd. - Grace Laboratories LLC - KeyNeurotek Pharmaceuticals AG - Luoxis Diagnostics - Neuro Assessment Systems - Neurohealing Pharmaceuticals - Neuren Pharmaceuticals Ltd. - Neurovive Pharmaceuticals AB - Oxygen Biotherapeutics Inc. - Phlogistix LLC - Remedy Pharmaceuticals Inc. - SFC Fluidics LLC - TEVA Pharmaceutical Industries Ltd. - Vasopharm For more information visit http://www.researchandmarkets.com/research/37...atic_brain
TEVA: 58.96 (-0.28)
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Pipeline Review 2015 - 10 Drug Profiles & 16 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mh4n22/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - RegeneRx Biopharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - Monoclonal Antibody for CIDP - NNZ-2591 - NP-1998 - NRP-2945 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides for Neuropathic Pain and Peripheral Neuropathy - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/mh4n22/peripheral
INSY: 25.65 (+0.64), PFE: 33.24 (+0.15), ACOR: 29.89 (-0.22)
Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 7:31AM CST
The report "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-n...eport.html .
PFE: 33.24 (+0.15)
Fragile X Syndrome Therapeutic Pipeline Market by Companies & Drugs Profile Review H2 2014
PRWeb - Sun Dec 07, 1:31PM CST
The report "Fragile X Syndrome Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. Fragile X Syndrome is the most common inherited form of mental problems and this disease caused by changes in a single X. Complete Report is Available @ http://www.rnrmarketresearch.com/fragile-x-sy...eport.html .
MRNS: 10.01 (+0.47), PRTK: 21.00 (+0.25)
Neuren's NNZ-2566 Successful in Demonstrating Clinical Benefit in Rett Syndrome Phase 2 Trial
Marketwired - Wed Nov 12, 12:26PM CST
Highlights:
NEU: 386.98 (+2.97)
Neuren Announces Results of the NNZ-2566 Clinical Trial for Rett Syndrome
PRWeb - Tue Nov 11, 7:11PM CST
Neuren Pharmaceuticals' human clinical trial using NNZ-2566 as a potential treatment for Rett syndrome (a trial supported by Rettsyndrome.org) was completed in September of this year. On November 11, Neuren announced the results of this phase 2 placebo-controlled study, which investigated the dosing of NNZ-2566 for safety and tolerability with efficacy being studied as well. The study was carried out at Baylor College of Medicine (Drs. Daniel Glaze and Jeffery Neul), University of Alabama Birmingham (Dr. Alan Percy) and Gillette Children's Specialty Healthcare (Drs. Tim Feyma and Art Beisang).
(0)
(0)Scroll down for more posts ▼